- Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024
- Invitation à assister à l'assemblée générale annuelle et extraordinaire des actionnaires de la Société qui se tiendra le 12 juin 2024
- Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer
- Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
- Information on the total number of voting rights and shares
- Informations sur le nombre total de droits de vote et d'actions
- Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation
- Nyxoah Fait Progresser sa Stratégie d'Accès aux Patients en Annonçant un Partenariat Stratégique avec l'American Association of Otolaryngology – Head & Neck Surgery Foundation
- Nyxoah Annonce que l'Étude Pivot DREAM U.S. Atteint les Critères d'Évaluation Primaires
- Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
More ▼
Key statistics
On Friday, Nyxoah SA (NYXH:NMQ) closed at 8.23, 105.75% above the 52 week low of 4.00 set on Jan 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.47 |
---|---|
High | 8.68 |
Low | 8.18 |
Bid | 8.00 |
Offer | 8.68 |
Previous close | 8.52 |
Average volume | 25.33k |
---|---|
Shares outstanding | 28.66m |
Free float | 14.55m |
P/E (TTM) | -- |
Market cap | 233.31m EUR |
EPS (TTM) | -1.55 EUR |
Data delayed at least 15 minutes, as of May 10 2024 20:59 BST.
More ▼